Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03214848 · ClinicalTrials.gov registry record · NA
Evaluation of an Intervention to Increase Post-abortion LARC Uptake.
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 1,314
- Enrollment target
NCT03214848: Completed NA study, sponsored by Emory University.
NCT03214848 is a NA study that has completed, run by Emory University. The registered enrollment target is 1,314 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03214848, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,314 participants
- Enrollment target
Study Summary
This is a randomized prospective study evaluating the impact of a brief contraceptive education intervention with optional referral for financial counseling on post abortion long-acting reversible contraceptive (LARC) uptake and contraceptive use at three months post abortion.
Primary Outcome
Proportion of LARC methods inserted immediately post abortion in the intervention and standard of care arms will be calculated based on data abstracted from patients' medical records.
Interventions
- BEHAVIORAL Contraceptive education prior to abortion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,314 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2018-02-21 |
| Phase | NA |
What the finished NCT03214848 record still lists
NCT03214848 is an interventional study that assigns participants to a tested intervention. Its 1,314 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Contraceptive education prior to abortion is the first listed.
NCT03214848 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03214848 about?
NCT03214848 is a clinical study titled "Evaluation of an Intervention to Increase Post-abortion LARC Uptake.". This is a randomized prospective study evaluating the impact of a brief contraceptive education intervention with optional referral for financial counseling on post abortion long-acting reversible contraceptive (LARC) uptake and contraceptive use at three months post abortion.
What is the current status of trial NCT03214848?
This trial is currently completed. It is a NA study. The enrollment target is 1,314 participants. The study started on 2017-09-13. Estimated completion is 2018-02-21.
What interventions are being tested in trial NCT03214848?
The interventions under investigation include: Contraceptive education prior to abortion (BEHAVIORAL).
Who is sponsoring clinical trial NCT03214848?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03214848's enrollment target sits among peer trials
1,314 76th of 2000 higher than 1,925 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- NCT05762302 · 1,316 participants · NA
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI